Pharmacogenomic-Guided Antidepressant Drug Prescribing in Cancer Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 300
Summary
- Conditions
- Anxiety
- Cancer
- Depression
- Depressive Disorder
- Generalized Anxiety Disorder
- Major Depressive Disorder
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Crossover AssignmentMasking: Single (Participant)Masking Description: Patients will be blinded to the genomic results for 12 weeks, with the 12 week time period starting at the time of antidepressant drug prescribing.Primary Purpose: Supportive Care
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03674138
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: James K Hicks, PharmD, PhD H. Lee Moffitt Cancer Center and Research Institute